|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500114625 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-16 08:09:21 |
|
注册时间: Date of Registration: |
2025-12-16 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
新生儿复杂先心病外科创新策略的多中心RCT及疗效评价体系研究 |
|
Public title: |
Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新生儿复杂先心病外科创新策略的多中心RCT及疗效评价体系研究 |
|
Scientific title: |
Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨起航 |
研究负责人: |
范太兵 |
|
Applicant: |
Qihang Yang |
Study leader: |
Taibing Fan |
|
申请注册联系人电话: Applicant telephone: |
+86 132 7142 1336 |
研究负责人电话:
Study leader's |
+86 150 3807 8538 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yangqihang25@163.com |
研究负责人电子邮件: Study leader's E-mail: |
fantaibing@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省郑州市郑东新区阜外大道1号 |
研究负责人通讯地址: |
河南省郑州市郑东新区阜外大道1号 |
|
Applicant address: |
No. 1 Fuwai Road, Zhengdong New District, Zhengzhou City, Henan Province |
Study leader's address: |
No. 1 Fuwai Road, Zhengdong New District, Zhengzhou City, Henan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
阜外华中心血管病医院 |
||
|
Applicant's institution: |
Central China Fuwai Hospital of Zhengzhou University |
||
|
研究负责人所在单位: |
阜外华中心血管病医院 |
||
|
Affiliation of the Leader: |
Central China Fuwai Hospital of Zhengzhou University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-18 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
阜外华中心血管病医院科研与新技术、新业务伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee for Scientific Research, New Technologies and New Services of Fuwai Huazhong Cardiovascular Disease Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-02-27 00:00:00 | ||
|
伦理委员会联系人: |
李牧蔚 |
||
|
Contact Name of the ethic committee: |
Muwei Li |
||
|
伦理委员会联系地址: |
河南省郑州市郑东新区阜外大道1号 |
||
|
Contact Address of the ethic committee: |
No. 1 Fuwai Road, Zhengdong New District, Zhengzhou City, Henan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 371 5868 0341 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
阜外华中心血管病医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Central China Fuwai Hospital of Zhengzhou University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河南省郑州市郑东新区阜外大道1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1 Fuwai Road, Zhengdong New District, Zhengzhou City, Henan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中央财政资金+单位自筹资金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Central Financial Funds + Self-raised Funds by the Unit |
||||||||||||||||||||||
|
研究疾病: |
新生儿复杂先天性心脏病 |
||||||||||||||||||||||
|
Target disease: |
Neonatal Complex Congenital Heart Disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
新生儿 CCHD 外科治疗手术时机尚存争议,本研究基于已建立的全国多中心先心病外科治疗数据库及产前产后一体化诊疗模式基础,开展新生儿 CCHD 最佳手术时机多中心 RCT 研究,制定危重新生儿 CCHD 创新综合治疗策略,并利用 RCT 研究数据进行疗效评价及建立评价体系,在全国逐步推广,使 CCHD 围术期死亡及非康复离院发生率降低 50%(2023 年全国新生儿先心病手术住院死亡率:6.5%;非康复离院率:12.66%),提高我国 CCHD 整体救治水平。 |
||||||||||||||||||||||
|
Objectives of Study: |
There remains controversy regarding the optimal timing of surgical treatment for neonatal CCHD (Complex Congenital Heart Disease). Based on the established national multi-center database for surgical treatment of congenital heart disease and the prenatal-postnatal integrated diagnosis and treatment model, this study will conduct a multi-center RCT (Randomized Controlled Trial) to explore the optimal surgical timing for neonatal CCHD. It will also develop innovative comprehensive treatment strategies for critically ill neonatal CCHD patients, use RCT data to evaluate treatment efficacy and establish an evaluation system. This system will be gradually promoted nationwide, aiming to reduce the incidence of perioperative mortality and non-recovery discharge in CCHD patients by 50% (National in-hospital mortality rate of neonatal congenital heart disease surgery in 2023: 6.5%; non-recovery discharge rate: 12.66%), thereby improving the overall level of CCHD treatment in China. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
第一部分: 1.入院前心脏彩超诊断为:TAPVC、 CoA/IAA、TGA、PA/IVS 或重症 PS的新生儿; 2.患者及家属依从性高,愿意签署知情同意书并同意完成1年随访及相关检查。 第二部分: 1.出生后确诊为 TAPVC、CoA、TGA、PA/IVS 及重症 PS 的早产儿(孕周<36 周出生)、低体重(体重<2.5kg)患儿; 2.出生后经内科治疗后病情仍不稳定需急诊手术的新生儿。 |
||||||||||||||||||||||
|
Inclusion criteria |
Part One: 1. Neonates diagnosed with TAPVC, CoA/IAA, TGA, PA/IVS, or severe PS via pre-admission cardiac echocardiography; 2. Patients and families demonstrating high compliance, willing to sign informed consent forms and agree to complete one year of follow-up and related examinations. Part Two: 1. Preterm infants (gestational age <36 weeks at birth) and low birth weight infants (<2.5kg) diagnosed postnatally with TAPVC, CoA, TGA, PA/IVS, or severe PS; 2. Neonates requiring emergency surgery due to persistent instability following medical management postnatally. |
||||||||||||||||||||||
|
排除标准: |
第一部分: 1.新生儿年龄>48h(入院时); 2.早产儿(孕周<36 周出生); 3.低出生体重(体重<2.5kg); 4.合并其他严重的心外畸形或严重复合心脏畸形; 5.术前呼吸、循环不稳定状态需急诊手术。 第二部分: 1.合并其他严重的心外畸形或严重复合心脏畸形; 2.临床资料不完整; 3.法定监护人不同意入组研究的。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Part One: 1. Neonatal age > 48 hours (at admission); 2. Preterm infant (gestational age < 36 weeks at birth); 3. Low birth weight (weight < 2.5 kg); 4. Concurrent severe extracardiac anomalies or complex cardiac malformations; 5. Preoperative respiratory or circulatory instability requiring emergency surgery. Part Two: 1. Concurrent severe extracardiac anomalies or complex cardiac malformations; 2. Incomplete clinical documentation; 3. Legal guardian refuses consent for study enrolment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-02-01 00:00:00至 To 2029-01-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-12-01 00:00:00 至 To 2029-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机分配序列由独立的统计师使用SAS 9.4软件生成,采用易侕中央随机系统隐蔽分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The random allocation sequence was generated by an independent statistician using SAS 9.4 software, and concealed allocation was implemented via the Yici Central Randomization System. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无;采用开放标签 |
|
Blinding: |
None; an open-label design was adopted |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
新生儿复杂先心病外科创新策略的多中心RCT及疗效评价体系研究临床试验电子数据采集系统(EDC) https://study.empoweredc.com/fwhz/login |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Electronic Data Capture (EDC) System for the Multicenter RCT and Efficacy Evaluation System Study on Surgical Innovative Strategies for Neonatal Complex Congenital Heart Disease https://study.empoweredc.com/fwhz/login |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture(EDC) System |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |